AR027394A1 - Uso de mirtazapina para el tratamiento de trastornos del sueno - Google Patents

Uso de mirtazapina para el tratamiento de trastornos del sueno

Info

Publication number
AR027394A1
AR027394A1 ARP010100585A ARP010100585A AR027394A1 AR 027394 A1 AR027394 A1 AR 027394A1 AR P010100585 A ARP010100585 A AR P010100585A AR P010100585 A ARP010100585 A AR P010100585A AR 027394 A1 AR027394 A1 AR 027394A1
Authority
AR
Argentina
Prior art keywords
mirtazapine
treatment
disorders
soil
medicament
Prior art date
Application number
ARP010100585A
Other languages
English (en)
Spanish (es)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR027394A1 publication Critical patent/AR027394A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP010100585A 2000-02-11 2001-02-09 Uso de mirtazapina para el tratamiento de trastornos del sueno AR027394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200499 2000-02-11

Publications (1)

Publication Number Publication Date
AR027394A1 true AR027394A1 (es) 2003-03-26

Family

ID=8171013

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100585A AR027394A1 (es) 2000-02-11 2001-02-09 Uso de mirtazapina para el tratamiento de trastornos del sueno

Country Status (25)

Country Link
US (1) US6933293B2 (enExample)
EP (4) EP1257278B1 (enExample)
JP (1) JP5039994B2 (enExample)
KR (1) KR20020069371A (enExample)
CN (2) CN1395487A (enExample)
AR (1) AR027394A1 (enExample)
AT (1) ATE317261T1 (enExample)
AU (1) AU780439B2 (enExample)
BR (1) BR0108261A (enExample)
CA (1) CA2396209C (enExample)
CO (1) CO5271706A1 (enExample)
CZ (1) CZ302368B6 (enExample)
DE (1) DE60117122T2 (enExample)
DK (1) DK1257278T3 (enExample)
ES (1) ES2258071T3 (enExample)
HK (1) HK1049122B (enExample)
HU (1) HUP0204391A3 (enExample)
IL (2) IL150290A0 (enExample)
NO (1) NO328007B1 (enExample)
PE (1) PE20011080A1 (enExample)
PL (1) PL206073B1 (enExample)
RU (1) RU2270680C2 (enExample)
SK (1) SK287396B6 (enExample)
WO (1) WO2001058453A1 (enExample)
ZA (1) ZA200205238B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152055A1 (en) * 2003-01-30 2004-08-05 Gliessner Michael J.G. Video based language learning system
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US20070298107A1 (en) * 2003-11-25 2007-12-27 Aurobindo Pharma Ltd. Pharmaceutical Compositions of Mirtazapine
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
AU2005292853C1 (en) * 2004-10-14 2010-08-05 Daikin Industries, Ltd. Atmosphere modifying method and spray agent and spray device used in the same
JP2006137748A (ja) * 2004-10-14 2006-06-01 Daikin Ind Ltd 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置
JP2007284363A (ja) * 2006-04-13 2007-11-01 Daikin Ind Ltd 噴霧剤
EP2146993B1 (en) 2007-04-11 2015-08-05 Merck Sharp & Dohme B.V. A method for the preparation of mirtazapine
PT3261645T (pt) 2015-02-27 2021-06-17 Dechra Ltd Estimulação do apetite, gestão da perda de peso, e tratamento da anorexia em cães e gatos
CN111053735A (zh) * 2020-02-25 2020-04-24 上海阶平医院管理有限公司 一种治疗失眠的冷敷凝胶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
HU215410B (hu) * 1992-10-07 1998-12-28 Akzo N.V. Eljárás enantiomerek elkülönítésére racém elegyből
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DK1030667T3 (da) 1997-11-14 2005-06-20 Akzo Nobel Nv Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö

Also Published As

Publication number Publication date
KR20020069371A (ko) 2002-08-30
CZ20022330A3 (cs) 2002-11-13
EP1658850A1 (en) 2006-05-24
HUP0204391A2 (en) 2003-05-28
CA2396209C (en) 2009-09-01
PL356721A1 (en) 2004-06-28
CN1395487A (zh) 2003-02-05
BR0108261A (pt) 2003-03-05
CO5271706A1 (es) 2003-04-30
RU2270680C2 (ru) 2006-02-27
ES2258071T3 (es) 2006-08-16
CZ302368B6 (cs) 2011-04-13
SK287396B6 (sk) 2010-08-09
JP5039994B2 (ja) 2012-10-03
US6933293B2 (en) 2005-08-23
EP1656937A1 (en) 2006-05-17
IL150290A (en) 2010-12-30
SK11442002A3 (sk) 2003-02-04
EP1257278B1 (en) 2006-02-08
ATE317261T1 (de) 2006-02-15
PE20011080A1 (es) 2001-10-18
HUP0204391A3 (en) 2005-03-29
NO20023803L (no) 2002-10-09
US20030022888A1 (en) 2003-01-30
IL150290A0 (en) 2002-12-01
HK1049122A1 (en) 2003-05-02
CN101229170A (zh) 2008-07-30
EP1257278A1 (en) 2002-11-20
DE60117122D1 (de) 2006-04-20
DK1257278T3 (da) 2006-06-12
PL206073B1 (pl) 2010-06-30
ZA200205238B (en) 2003-09-29
AU3024701A (en) 2001-08-20
NO328007B1 (no) 2009-11-09
AU780439B2 (en) 2005-03-24
HK1049122B (en) 2006-04-21
CA2396209A1 (en) 2001-08-16
NO20023803D0 (no) 2002-08-09
DE60117122T2 (de) 2006-07-27
RU2002124141A (ru) 2004-03-10
EP2283840A1 (en) 2011-02-16
WO2001058453A1 (en) 2001-08-16
JP2003522147A (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
ES2603086T3 (es) Uso de la daptomicina
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
NO20014519L (no) Apomorfin- og sildenafilpreparat
AR039130A2 (es) Metodo de administracion de un agente farmaceuticamente activo a un ojo humano
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
AR032132A1 (es) Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
UY25544A1 (es) Forma de dosificación de nefazodona
BRPI0418213A (pt) forma de dosagem, e, método para tratar dor em um paciente em necessidade do mesmo
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
CO5271706A1 (es) Unidad de dosis de mirtazapina para el tratamiento de transtornos del sueno
PY0218122A (es) Metodo para el tratamiento del insomnio primario
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
AR025343A1 (es) Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure